mortality/aging
• lifespan after pIpC treatment is shorter than in controls and in mutant nice with no wild-type Pkn3 alleles
|
neoplasm
• develop myeloproliferative neoplasms in the spleen 2 weeks after pIpC treatment
|
• all eventually develop T cell acute lymphoblastic leukemia after pIpC treatment at 6 weeks of age
|
hematopoietic system
• at 2 weeks after pIpC treatment
|
• at 2 weeks after pIpC treatment
|
• increase in the number of hematopoietic stem cells in the spleen 2 weeks after pIpC treatment
|
endocrine/exocrine glands
• at 2 weeks after pIpC treatment
|
immune system
• at 2 weeks after pIpC treatment
|
• at 2 weeks after pIpC treatment
|
growth/size/body
• at 2 weeks after pIpC treatment
|